In patients with T2D and high cardiovascular risk, SGLT2 inhibitor treatment significantly lowers the risk of cardiovascular events (5,6) and slows the progression of chronic kidney disease toward renal failure (7,8). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.